The research, conducted in rhesus macaques infected with simian immunodeficiency virus, examined the consequence of administering an inhibitor of BCL-2 at the same time antiretroviral therapy was begun. BCL-2 is the founding member of a family of proteins that govern the intrinsic pathway of apoptosis, the programmed death machinery residing in the mitochondria of every nucleated cell. These proteins operate through a delicate balance: pro-survival members such as BCL-2, BCL-XL and MCL-1 sequester pro-apoptotic effectors like BAX and BAK, keeping the mitochondrial outer membrane intact. When the balance tips — through cellular stress, growth-factor withdrawal, or pharmacological inhibition — the effectors oligomerize, the membrane permeabilizes, and cytochrome c is released, committing the cell irreversibly to death. Lymphoid cells, and in particular long-lived memory T cells, depend heavily on BCL-2 for their extended lifespan, which is precisely why the latent reservoir exploits this pathway to survive the years of treatment that follow infection.

The rationale for the intervention rests on a conceptual reframing of the reservoir problem. Latency-reversing approaches attempt to shock the virus out of hiding and rely on the immune system or viral cytopathic effects to destroy the cells that harbor it. The BCL-2 strategy instead attacks the survival advantage of the infected cells themselves, arguing that if a latently infected cell can be nudged across the apoptotic threshold while the patient’s cells are protected from ongoing infection by ART, the intact reservoir should contract without the need for viral reactivation. This idea draws on clinical experience from oncology, where selective BCL-2 inhibitors such as venetoclax have transformed the treatment of chronic lymphocytic leukemia by triggering apoptosis in malignant lymphocytes that overexpress the protein. Repurposing that pharmacology for HIV cure research has long been proposed in model systems, but rigorous in vivo evidence that the approach works against the intact reservoir, in a setting that faithfully recapitulates human infection, had been lacking.

In the macaque study, animals infected with SIV received antiretroviral therapy accompanied by BCL-2 inhibition beginning at the time of treatment initiation, while control animals received ART alone. The investigators then tracked the composition of the reservoir over the course of suppression using quantitative methods capable of distinguishing intact proviruses from defective ones — an essential technical distinction, since measures that count all proviral DNA or rely solely on replication-competence assays can be dominated by defective genomes that pose no clinical threat. Single-genome sequencing approaches, in which viral genomes are amplified and analyzed individually, allow researchers to categorize each provirus as genetically intact or defective and to estimate the true size of the replication-competent reservoir. It is this intact-reservoir metric that predicts how long rebound would take after treatment interruption and that any realistic cure strategy must reduce.

The results demonstrated that the combined regimen reduced the frequency of intact SIV proviruses to a greater degree than ART alone. This finding carries significance well beyond the raw numbers. In the standard macaque model of ART suppression, the intact reservoir decays slowly and incompletely, mirroring the stubborn persistence observed in treated people living with HIV. An intervention applied at the start of therapy that accelerates this decay suggests that early intervention — the period in which the reservoir is being seeded and consolidated — represents a window of vulnerability that has been underexploited. Cells harboring latent virus during this period may be especially dependent on BCL-2-mediated survival, perhaps because they belong to recently activated, cytokine-dependent lineages that have not yet achieved the deep quiescence of long-term memory cells, or because the perturbation of the cellular environment by treatment initiation renders them more sensitive to apoptotic priming.

Timing is a theme that recurs throughout the reservoir literature, and the placement of BCL-2 inhibition at therapy initiation rather than during established suppression is one of the study’s most consequential design choices. A large body of observational work in humans has shown that the size of the reservoir is strongly determined by how quickly ART is started after infection; treatment during acute infection produces a smaller reservoir that, in rare cases, permits sustained remission after analytic treatment interruption, as famously demonstrated in the Mississippi child and a cohort of post-treatment controllers. The macaque data now suggest that pharmacological manipulation of cell-survival pathways can augment that early-treatment advantage. By pairing BCL-2 inhibition with the first days of ART, the intervention may eliminate infected cells at a stage when the reservoir is most dynamic and most chemically vulnerable, before proviruses disperse into the heterogeneous, long-lived populations that make later cure attempts so difficult.

The mechanistic logic of the approach also deserves attention. Unlike broadly neutralizing antibodies or therapeutic vaccines, which act on the viral side of the host-pathogen interface, BCL-2 inhibitors modulate host biology, raising the specter of on-target toxicity: excessive apoptosis of bystander lymphocytes, immunosuppression, or hematologic complications. The anti-apoptotic family is redundant, with different members protecting different cell lineages, and selective inhibition of BCL-2 alone is generally tolerated in leukemia patients, where the drug’s therapeutic window has been mapped in detail. Nevertheless, translating a cancer dosing schedule to an infectious-disease indication in otherwise healthy carriers requires careful attention to CD4+ and CD8+ T cell counts, neutrophil dynamics, and the possibility of transient cytokine release from dying cells. The macaque model, with its close immunological correspondence to humans and its validated SIV challenge system, provides the appropriate preclinical platform for establishing that window, and the observed reduction of the intact reservoir without catastrophic loss of immune competence represents an encouraging early signal.

Broader implications extend to the architecture of cure strategies as a whole. The field has converged on the view that no single intervention will eradicate the reservoir; combination regimens — pairing a reservoir-reduction modality with an immune effector such as broadly neutralizing antibodies, and a means of protecting uninfected cells such as long-acting antiretrovirals — are widely considered necessary. A BCL-2-directed agent could plausibly occupy the reduction slot in such combinations, working synergistically with latency-reversal approaches by first shrinking the intact pool and then rendering residual infected cells more susceptible to immune clearance. The study also reinforces a growing appreciation that the intracellular death machinery is a legitimate pharmacological target in virology, opening a search for other host-survival dependencies — metabolic, epigenetic, or signaling-based — that latently infected cells might share and that could be exploited with existing drugs.

Substantial questions remain before any human application. The durability of the reduction, its reproducibility across animals with different reservoir sizes and infection timelines, the effect of delaying inhibition until after prolonged suppression, and the interaction with viral rebound dynamics all require further investigation. Human reservoir biology differs from the macaque model in heterogeneity and scale, and the intact reservoir in chronically infected adults is orders of magnitude larger than in early-treated cases, which may limit what a survival-pathway intervention can achieve late in disease. Yet the study’s core contribution is conceptual as much as empirical: it shows in a rigorous animal model that the intact reservoir — not merely the total proviral burden — can be attacked by targeting the host determinants of cellular longevity, and that treatment initiation offers a pharmacologically exploitable moment to do so. As cure research matures beyond proof-of-concept latency reversal, strategies of this kind may help define a realistic path toward functional remission, in which residual virus is so scarce and so fragile that antiretroviral therapy can be safely suspended for extended periods.

Subject of Research: BCL-2 inhibition combined with antiretroviral therapy to reduce the intact simian immunodeficiency virus reservoir in macaques

Article Title: BCL-2 inhibition at antiretroviral therapy initiation reduces the intact SIV reservoir in macaques

Article References: Wiche Salinas, T. R., Harper, J., Deleage, C., Nguyen, K., Auger, J., Flores, H. R., Kaushik, S. R., Wilkes, A. C., Stammen, R. L., Wood, J. S., Easley, K. A., Nelson, S., Tharp, G. K., Bosinger, S. E., Cottrell, M. L., Kose, E., Immonen, T. T., Lifson, J. D., Laird, G. M., … Paiardini, M. (2026). BCL-2 inhibition at antiretroviral therapy initiation reduces the intact SIV reservoir in macaques. Nature Microbiology. https://doi.org/10.1038/s41564-026-02464-7

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02464-7

Keywords: HIV cure, SIV, viral reservoir, BCL-2, apoptosis, antiretroviral therapy, latency, CD4+ T cells, macaques, provirus, treatment interruption, Nature Microbiology